Spectral Med Inc (EDT.TO) saw a slight increase in its share price this week amidst regulatory updates and financial disclosures.
This week, Spectral Med Inc's stock closed at C$1.16, reflecting a 4.50% increase on Wednesday, although it has experienced a modest decline of 0.85% over the past week. Investors are closely monitoring the company's developments regarding its regulatory pathway and financial stability as it navigates the health care sector.
Advertisement
Spectral Med Inc
EDT.TO
EDT.TO
Spectral Med Inc
WealthAwesomeMarket cap
$325.84M
52W high
$1.65
52W low
$1.03
1W change
-5.53%
Beta
0.22
Analyst Price Targets
Based on analyst covering EDT · as of Sep 17, 2026
Wall Street analysts forecast EDT stock price to rise 183.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.15
+183.8% Upside
Current Price
C$1.11
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EDT's historical volatility
30-Day Vol
50.5%
Annualized
90-Day Vol
37.0%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.93
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.05 | C$0.88 – C$1.25 |
| 60 trading days | C$0.99 | C$0.77 – C$1.26 |
| 90 trading days | C$0.93 | C$0.69 – C$1.26 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Despite the recent uptick in stock price, Spectral Med Inc continues to face challenges with its market performance year-to-date, prompting investors to consider the implications of its ongoing regulatory discussions and financial results.
Spectral Med Inc's stock price has fluctuated between C$1.03 and C$1.65 over the past year.
Currently, the stock is trading at approximately 21% of its 52-week range, indicating a significant distance from its yearly high.
Bull case
The company's recent update from the FDA indicated that no additional clinical trials are needed, which could speed up the approval process for its product, Toraymyxin™. Analysts remain optimistic, with an average target price significantly above the current trading level.
Bear case
Despite the positive FDA update, Spectral Med's performance this year shows a decline of nearly 16%. Concerns about its financial health are raised by fundamentals such as a negative return on equity and profit margin.
Recent Price Action
Advertisement
Spectral Med Inc (EDT.TO) closed at C$1.16 on Wednesday, marking a 4.50% increase for the day. However, the stock has experienced a slight decline of 0.85% over the past week and a more substantial fall of 15.94% year-to-date. The volume of shares traded on Wednesday was 115,365, significantly higher than the 20-day average of 52,733 shares, indicating increased investor interest.
Company News and Developments
No major news announcements were released this week; however, a recent update from the company regarding its meeting with the FDA on September 11, 2026, indicated that the FDA did not require additional clinical trials for its product, Toraymyxin™. This development is crucial as it suggests that the regulatory timeline may remain intact, which could positively impact investor sentiment moving forward.
Technical Picture
From a technical perspective, Spectral Med's stock is currently below its 50-day moving average of C$1.29 and its 200-day moving average of C$1.34, reflecting a bearish trend. The stock's 52-week range has been between C$1.03 and C$1.65, placing it at approximately 21% of this range. With a low beta of 0.22, the stock has shown less volatility compared to the broader market.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
